摘要
目的评价新辅助化疗对肌层浸润性膀胱癌患者预后的影响。方法通过PubMed、Cochrane library、万方、康健、CBMdisc、EMBASE等数据库收集国内外已发表的相关前瞻性随机对照研究,按预设的标准进行筛选,共12个研究符合纳入标准,总样本量3286例,新辅助治疗组1636例,对照组1650例,对纳入研究进行质量评价,并提取数据进行Meta分析。结果新辅助化疗组与对照组相比,死亡风险优势比0.85(95%CI0.73～0.98,P=0.03)。将12个纳入研究按新辅助化疗方案进行亚组分析,单用铂剂组显示新辅助化疗并没有降低患者死亡风险,而以铂剂为基础的多药联合新辅助化疗可降低患者死亡风险(OR0.79,95%CI0.67～0.92,P=0.0004)。结论新辅助化疗,尤其是以铂剂为基础的联合化疗方案,适用于肌层浸润性膀胱癌的治疗,可改善预后。
Objective To evaluate the effect of neoadjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer.Methods Published prospective randomized controlled trials（RCT） on neoadjuvant chemotherapy for muscle-invasive bladder cancer were searched and screened in Pubmed,EMBASE,CBMdisc,Cochrane library and Wanfang databases under preset standards.The data from eligible studies were pooled through Meta-analysis.Results Totally 12 trials including 3 286 patients were eligible to the criteria（1 636 in study group and 1 650 in control group）.The odds radio of all trails tended to favour neoadjuvant chemotherapy（OR=0.85,95% CI 0.73 to 0.98,P=0.03）.Platinum-based combination chemotherapy showed a significant reduction in risk of death（OR=0.79,95% CI=0.67 to 0.92,P=0.0004）,but there was no evidence to support the use of single-agent platinum.Conclusions Neoadjuvant chemotherapy especially platinum-based combination chemotherapy is beneficial to muscle-invasive bladder cancer patients.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2011年第2期196-199,共4页
Journal of Third Military Medical University
关键词
新辅助化疗
肌层浸润性膀胱癌
META分析
neoadjuvant chemotherapy
muscle-invasive bladder cancer
Meta-analysis
